IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE

(19)

(11)

EP 1 934 239 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	04.11.2015 Bulletin 2015/45

(45)	Mention of the grant of the patent:
	15.07.2015 Bulletin 2015/29

(21)	Application number: 06825856.5

(22)	Date of filing: 12.10.2006

(51)

International Patent Classification (IPC):

A61K 48/00^(2006.01)
A61K 39/00^(2006.01)

C12N 15/117^(2010.01)

(86)	International application number:
	PCT/US2006/039954

(87)	International publication number:
	WO 2007/047396 (26.04.2007 Gazette 2007/17)

(54)

IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE

IMMUNREGULATORISCHE OLIGONUKLEOTID (IRO)-VERBINDUNGEN ZUR MODULATION VON IMMUNREAKTIONEN AUF DER BASIS VON TOLL-LIKE-REZEPTOREN

COMPOSES D'OLIGONUCLEOTIDES DE REGULATION IMMUNE (IRO) PERMETTANT DE MODULER UNE REPONSE IMMUNE FONDEE SUR UN RECEPTEUR DE TYPE TOLL

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30)

Priority:

12.10.2005 US 726034 P
21.03.2006 US 784243 P
13.09.2006 US 825440 P

(43)	Date of publication of application:
	25.06.2008 Bulletin 2008/26

(60)	Divisional application:
	10013989.8 / 2343307
	11000806.7 / 2341059
	15168723.3

(73)	Proprietor: Idera Pharmaceuticals, Inc.
	Cambridge, MA 02139 (US)

(72)	Inventors:
	KANDIMALLA, Ekambar, R. Hopkinton, MA 01748 (US) WANG, Daqing Bedford, MA 01730 (US) LI, Yukui Newton, MA 02465 (US) YU, Dong Westboro, MA 01581 (US) ZHU, Fu-Gang Bedford, MA 01730 (US) BHAGAT, Lakshmi Framingham, MA 01702 (US) SUDHIR, Agrawal Shrewsbury, MA 01545 (US)

(74)	Representative: Schnappauf, Georg et al
	ZSP Patentanwälte Partnerschaftsgesellschaft Radlkoferstrasse 2 81373 München 81373 München (DE)

(56)

References cited: :

WO-A-03/103586
WO-A2-2004/094671
WO-A2-2007/038720
US-A1- 2005 239 733

WO-A1-03/103708
WO-A2-2005/007672
US-A1- 2004 097 719

LENERT PETAR ET AL: "Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells." ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 13, no. 3, 2003, pages 143-150, XP002506105 ISSN: 1087-2906
YU DONG ET AL: "Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences" JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 45, no. 20, 26 September 2002 (2002-09-26), pages 4540-4548, XP002478300 ISSN: 0022-2623 [retrieved on 2002-08-06]
KANDIMALLA E R ET AL: "A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 100, no. 24, 1 January 2003 (2003-01-01), pages 14303-14308, XP002990545 ISSN: 0027-8424

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).